[{"orgOrder":0,"company":"EG 427","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"EG110A","moa":"Botulinum toxin fragment","graph1":"Urology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EG 427 \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : The funding will be used to advance company's pipeline, culminating in the Investigational New Drug application filing for the first clinical study of its lead product, EG110A which targets the silencing of type-C sensory neuronsm and is being developed ...

                          Product Name : EG110A

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 13, 2023

                          Lead Product(s) : EG110A

                          Therapeutic Area : Urology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : $20.2 million

                          Deal Type : Series A Financing

                          blank